Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom's Q2 Loss Narrows 35 Percent as Revenue Rises and R&D Spend Drops

NEW YORK (GenomeWeb News) – Sequenom today said second-quarter net loss narrowed on a 15-percent increase in revenues and reduced R&D spending.
 
The results caused shares in the company to trade up 6.9  percent, or $.11, at $1.70 mid-afternoon today.
 
Receipts for the three months ended June 30 increased to $7 million from $6 million year over year.
 
R&D costs declined almost 20 percent to $2.4 million from $3 million from the comparable quarter a year ago.
 
Sequenom said net loss shrank 35 percent to $4 million for the second quarter compared to $6 million last year.
 
Sequenom had $32.6 million in cash and cash equivalents as of June 30. The cash on hand includes the net proceeds of approximately $30 million from a private placement of common stock in June.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more